Cargando…

Single-cell transcriptomics reveals the effect of PD-L1/TGF-β blockade on the tumor microenvironment

BACKGROUND: The anti-tumor activity of anti-PD-1/PD-L1 therapies correlates with T cell infiltration in tumors. Thus, a major goal in oncology is to find strategies that enhance T cell infiltration and efficacy of anti-PD-1/PD-L1 therapy. TGF-β has been shown to contribute to T cell exclusion, and a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lim, Yoong Wearn, Coles, Garry L., Sandhu, Savreet K., Johnson, David S., Adler, Adam S., Stone, Erica L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2021
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8147417/ https://www.ncbi.nlm.nih.gov/pubmed/34030676 http://dx.doi.org/10.1186/s12915-021-01034-z

Ejemplares similares

Predicting antibody binders and generating synthetic antibodies using deep learning
por: Lim, Yoong Wearn, et al.
Publicado: (2022)

Remodeling the tumor microenvironment via blockade of LAIR-1 and TGF-β signaling enables PD-L1–mediated tumor eradication
por: Horn, Lucas A., et al.
Publicado: (2022)

Distinct immune microenvironment profiles of therapeutic responders emerge in combined TGFβ/PD-L1 blockade-treated squamous cell carcinoma
por: Strait, Alexander A., et al.
Publicado: (2021)

TGF-β attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells
por: Mariathasan, Sanjeev, et al.
Publicado: (2018)

Blockade of Treg derived TGF-β abrogates suppression of effector T cell function within the tumor microenvironment
por: Budhu, Sadna, et al.
Publicado: (2013)

B-cells Drive Response to PD-1 Blockade in Glioblastoma Upon Neutralization of TGFβ-mediated Immunosuppression
por: Hou, David, et al.
Publicado: (2023)

TGFβ: Signaling Blockade for Cancer Immunotherapy
por: Chen, Szu-Ying, et al.
Publicado: (2022)

Blockade of surface bound TGF-β abrogates Treg suppression of effector T cell function within the tumor microenvironment
por: Budhu, Sadna, et al.
Publicado: (2014)

Pan-TGFβ inhibition by SAR439459 relieves immunosuppression and improves antitumor efficacy of PD-1 blockade
por: Greco, Rita, et al.
Publicado: (2020)

TGF-β inhibition can overcome cancer primary resistance to PD-1 blockade: A mathematical model
por: Siewe, Nourridine, et al.
Publicado: (2021)

Synergistic efficacy of simultaneous anti-TGF-β/VEGF bispecific antibody and PD-1 blockade in cancer therapy
por: Niu, Mengke, et al.
Publicado: (2023)

Affinity maturation of antibodies by combinatorial codon mutagenesis versus error-prone PCR
por: Simons, Jan Fredrik, et al.
Publicado: (2020)

Selective inhibition of TGF-β1 produced by GARP-expressing Tregs overcomes resistance to PD-1/PD-L1 blockade in cancer
por: de Streel, Grégoire, et al.
Publicado: (2020)

Dual PD-L1 and TGF-b blockade in patients with recurrent respiratory papillomatosis
por: Robbins, Yvette, et al.
Publicado: (2021)

Enhanced neoepitope-specific immunity following neoadjuvant PD-L1 and TGF-β blockade in HPV-unrelated head and neck cancer
por: Redman, Jason M., et al.
Publicado: (2022)

Enhanced neoepitope-specific immunity following neoadjuvant PD-L1 and TGF-β blockade in HPV-unrelated head and neck cancer
por: Redman, Jason M., et al.
Publicado: (2023)

Selecting suitable chemotherapies for PD-1/PD-L1 blockade to optimize the tumor immune microenvironment
por: Koyama, Shohei, et al.
Publicado: (2018)

TGFβ Signaling in the Pancreatic Tumor Microenvironment
por: Principe, Daniel R., et al.
Publicado: (2021)

TGFβ and the Tumor Microenvironment in Colorectal Cancer
por: Waldner, Maximilian J., et al.
Publicado: (2023)

Integrin-α(V)-mediated activation of TGF-β regulates anti-tumour CD8 T cell immunity and response to PD-1 blockade
por: Malenica, Ines, et al.
Publicado: (2021)

The abscopal effect of local radiotherapy is induced by TGFβ blockade
por: Diamond, Julie, et al.
Publicado: (2013)

A potential treatment of COVID-19 with TGF-β blockade
por: Chen, WanJun
Publicado: (2020)

Treg-Dominant Tumor Microenvironment Is Responsible for Hyperprogressive Disease after PD-1 Blockade Therapy
por: Wakiyama, Hiroaki, et al.
Publicado: (2022)

Targeting TGFβR2‐mutant tumors exposes vulnerabilities to stromal TGFβ blockade in pancreatic cancer
por: Huang, Huocong, et al.
Publicado: (2019)

Combined mitoxantrone and anti-TGFβ treatment with PD-1 blockade enhances antitumor immunity by remodelling the tumor immune landscape in neuroblastoma
por: Lucarini, Valeria, et al.
Publicado: (2022)

An integrative approach of digital image analysis and transcriptome profiling to explore potential predictive biomarkers for TGFβ blockade therapy
por: Pomponio, Robert, et al.
Publicado: (2022)

Correction: Dual PD-L1 and TGF-b blockade in patients with recurrent respiratory papillomatosis
Publicado: (2021)

Ambra1 modulates the tumor immune microenvironment and response to PD-1 blockade in melanoma
por: Frias, Alex, et al.
Publicado: (2023)

Translating the combination of TGFβ blockade and radiotherapy into clinical development in glioblastoma
por: Zhang, Mengxian, et al.
Publicado: (2012)

TGF-β and the Tissue Microenvironment: Relevance in Fibrosis and Cancer
por: Caja, Laia, et al.
Publicado: (2018)

The role of TGF-β in the tumor microenvironment of pancreatic cancer
por: Luo, Qiang, et al.
Publicado: (2022)

Direct and Indirect Effect of TGFβ on Treg Transendothelial Recruitment in HCC Tissue Microenvironment
por: Dituri, Francesco, et al.
Publicado: (2021)

Combined PD-L1/TGFβ blockade allows expansion and differentiation of stem cell-like CD8 T cells in immune excluded tumors
por: Castiglioni, Alessandra, et al.
Publicado: (2023)

Cyclin G2 reverses immunosuppressive tumor microenvironment and potentiates PD-1 blockade in glioma
por: Li, Sen, et al.
Publicado: (2021)

Genomic features and tumor immune microenvironment alteration in NSCLC treated with neoadjuvant PD-1 blockade
por: Wang, Shuhang, et al.
Publicado: (2022)

Dual targeting of TGF-β and PD-L1 via a bifunctional anti-PD-L1/TGF-βRII agent: status of preclinical and clinical advances
por: Lind, Hanne, et al.
Publicado: (2020)

Intertumoral Differences Dictate the Outcome of TGF-β Blockade on the Efficacy of Viro-Immunotherapy
por: Groeneveldt, Christianne, et al.
Publicado: (2023)

Therapeutic activity of GARP:TGF-β1 blockade in murine primary myelofibrosis
por: Lecomte, Sara, et al.
Publicado: (2023)

Targeting immune cell types of tumor microenvironment to overcome resistance to PD-1/PD-L1 blockade in lung cancer
por: Wang, Man, et al.
Publicado: (2023)

TGFβ1 microenvironment determines dendritic cell development
por: Seré, Kristin, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_es0pp44r199u5ksmp4t1mrdav8